"set it and forget it": Women's perceptions and opinions of long-acting topical vaginal gels

AIDS and Behavior

Volumn 18, Issue 5, 2014, Pages 862-870

  Van Den Berg, Jacob J ^a,b,i   Rosen, Rochelle K ^a,c   Bregman, Dana E ^a,j   Thompson, Lara A ^a,k   Jensen, Kathleen M ^a,l   Kiser, Patrick F ^d,e   Katz, David F ^f,g   Buckheit, Karen ^h   Buckheit, Robert W ^h   Morrow, Kathleen M ^a,b  

^a Brown University Centers for Behavioral and Preventive Medicine   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d Department of Electrical and Computer Engineering   (United States)

^e Northwestern University   (United States)

^f Duke University   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ImQuest Biosciences   (United States)

ⁱ MIRIAM HOSPITAL   (United States)

^j DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^k BASTYR UNIVERSITY   (United States)

^l UNIVERSITY OF TEXAS AT AUSTIN   (United States)

more..

Author keywords

Acceptability; HIV STI prevention; Long acting vaginal gels; Microbicides; Women

Indexed keywords

AGENTS USED INTRAVAGINALLY; TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; FEMALE; HIV INFECTIONS; HUMAN; INFORMATION PROCESSING; INTERVIEW; INTRAVAGINAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PERCEPTION; PSYCHOLOGY; QUALITATIVE RESEARCH; SEXUALLY TRANSMITTED DISEASES; TIME;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; PATIENT ACCEPTANCE OF HEALTH CARE; PERCEPTION; QUALITATIVE RESEARCH; SEXUALLY TRANSMITTED DISEASES; TIME FACTORS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84899646782     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0652-4     Document Type: Article

References (30)

1. World Health Organization (WHO). Global summary of the AIDS epidemic. Geneva: World Health Organization, 2011. http://www.who.int/hiv/data/2012-epi- core-en.png. Accessed Aug 13 2013.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-34.
5. WHO. Microbicides. 2013. http://www.who.int/hiv/topics/microbicides/ microbicides/en/. Accessed Aug 13, 2013.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
7. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009;11:78.
8. Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS. 2008;3:558-66.
9. AVAC. Ongoing microbicide trials. 2013. http://data.avac.org/ OngoingMicrobicideTrials.aspx. Accessed Aug 13 2013.
10. Johnson TJ, Clark MR, Albright TH, et al. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012;56:6272-83.
11. Tasoglu S, Rohan LC, Katz DF, Szeri AJ. Transient swelling, spreading, and drug delivery by a dissolved anti-HIV microbicide-bearing film. Phys Fluids. 2013;25:31901.
12. Carballo-Diéguez A, Dolezal C, Bauermeister JA, O'Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483-7.
13. Mohammed Fayaz A, Ao Z, Girilal M, et al. Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomed. 2012;7:5007-18.
14. Ball C, Krogstad E, Chaowanachan T, Woodrow KA. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS ONE. 2012;7:e49792.
15. Singer R, Mawson P, Derby N, et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med. 2012;4:150ra123.
16. Baum MM, Butkyavichene I, Gilman J, et al. An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci. 2012;101:2833-43.
17. Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012;14:62-77.
18. Clark MR, Johnson TJ, McCabe RT, et al. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci. 2012;101:576-87.
19. Romano J, Variano B, Coplan P, et al. AIDS Res Hum Retroviruses. 2009;25:483-8.
20. Severy LJ, Newcomer S. Critical issues in contraceptive and STI acceptability research. J Soc Issues. 2005;61:45-65.
21. Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9(1):121-31.
22. Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319-30.
23. Darroch JE, Frost JJ. Women's interest in vaginal microbicides. Fam Plan Perspect. 1999;31(1):16-23.
24. Hammett TM, Mason TH, Joanis CL, et al. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex Transm Dis. 2000;27(2):119-26.
25. Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006;20(17):2141-8.
26. Kamali A, Byomire H, Muwonge C, et al. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect. 2010;86(3):222-6.
27. Morrow KM, Fava JL, Rosen RK, et al. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses. 2013. doi: 10.1089/AID.2013.0099.
28. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
29. Turner AN, Van Damme K, Jamieson DJ, et al. Predictors of adherent use of diaphragms and microbicide gel in a four-arm, randomized pilot study among female sex workers in Madagascar. Sex Transm Dis. 2009;36(4):249-57.
30. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.